|
Early Translational I |
J. William Langston |
Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson's disease research and drug discovery |
$3,698,646 |
|
Tools and Technologies II |
Birgitt Schuele |
Editing of Parkinson’s disease mutation in patient-derived iPSCs by zinc-finger nucleases |
$1,327,983 |
|
Basic Biology III |
R. Jeremy Nichols |
Understanding the role of LRRK2 in iPSC cell models of Parkinson's Disease |
$1,482,822 |
|
Quest - Discovery Stage Research Projects |
Birgitt Schuele |
CRISPR/dCas9 mutant targeting SNCA promoter for downregulation of alpha-synuclein expression as a novel therapeutic approach for Parkinson’s disease |
$1,288,415 |
